Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Direct observations: clinical cases, poisoning incidents and other

Currently viewing:

Administrative data

Endpoint:
direct observations: clinical cases, poisoning incidents and other
Type of information:
migrated information: read-across based on grouping of substances (category approach)
Adequacy of study:
key study
Study period:
Not reported
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Study well documented, meets generally accepted scientific principles, acceptable for assessment
Cross-referenceopen allclose all
Reason / purpose for cross-reference:
reference to same study
Reason / purpose for cross-reference:
reference to other study

Data source

Reference
Reference Type:
publication
Title:
Unnamed
Year:
1984

Materials and methods

Study type:
study with volunteers
Endpoint addressed:
repeated dose toxicity: oral
Principles of method if other than guideline:
A clinical trial was conducted on healthy human volunteers for six weeks to evaluate the effect of the test material on immune response and plasma lipoproteins.
GLP compliance:
no

Test material

Constituent 1
Details on test material:
- Name of test material (as cited in study report): Zinc sulfate

Method

Type of population:
general
Subjects:
- Number of subjects exposed: 11
- Sex: Male
- Age: Adult
- Known diseases: None
- Other: Subjects were instructed not to change dietary intake or exercise during the study period
Ethical approval:
not specified
Route of exposure:
oral
Reason of exposure:
intentional
Exposure assessment:
measured
Details on exposure:
Clinical trial: 150 mg Zn (as ZnSO4) was administered to healthy volunteers twice a day for six weeks.
Examinations:
- Haematology: Total number of lymphocytes and function, T and B cells, polymorphonuclear (PMN) leukocyte function, phagocytosis and bactericidal capacity
- Estimation of plasma lipoproteins: Total cholesterol, triglyceride, HDL & LDL-cholesterol
- Estimation of plasma Zn levels by atomic absorption spectrophotometry
Medical treatment:
No

Results and discussion

Clinical signs:
No side effects
Results of examinations:
PLASMA LIPOPROTEINS:
- HDL-cholesterol: Decreased from 42 to 29 mg/dL;
- LDL-cholesterol: Increased from 110 to 127 mg/dL;
- LDL/HDL ratio (atherogenic index): Increased from 2.6 to 4.2
- Total cholesterol and triglyceride levels: No significant change

PLASMA ZINC LEVELS: Increased from 83 to 199 µg/dL

HAEMATOLOGY:
Total lymphocytes count, T and B cells, and T-lymphocyte subsets: No significant change

IMMUNE RESPONSE:
- Polymorphonuclear(PMN) migration response to chemotactic migration: Decreased (292 ± 57 PMN/10 high-power field) during the period of Zinc administration and increased (576 ± 114 PMN/10 high-power field) to baseline values (632 ± 101 PMN/10 high-power field) several weeks after stopping the supplements
- Phagocytosis of opsonized bacteria: Impaired
- Bactericidal capacity: Slightly reduced but not significant

For details see the following tables in the attached PDF:
Table 1: Plasma Zinc Levels and Polymorphonuclear (PMN) Leukocyte Function
Table 2: Lymphocyte Number
Table 3: Serum Lipid and Lipoprotein Concentrations
Effectivity of medical treatment:
Not applicable
Outcome of incidence:
Not applicable

Any other information on results incl. tables

None

Applicant's summary and conclusion

Conclusions:
Under the test conditions, moderately large amount of oral Zinc supplement was observed to be associated with significant impairment of lymphocyte and polymorphonuclear functions.
Executive summary:

A clinical trial was conducted on 14 healthy human volunteers for six weeks to evaluate the effect of the test material (150 mg Zn as ZnSO4, twice a day for six weeks) on immune response and plasma lipoproteins.

 

A reduction in lymphocyte stimulation response to phyto-hemagglutinin as well as chemotaxis and phagocytosis of bacteria by polymorphonuclear leukocytes was observed. Serum high-density lipoprotein concentration decreased significantly and low-density lipoprotein level increased slightly.

 

Under the test conditions, moderately large amount of oral Zinc supplement was observed to be associated with significant impairment of lymphocyte and polymorphonuclear functions.